Addex Therapeutics vs Lyell Immunopharma
Addex Therapeutics and Lyell Immunopharma are similar in size: $36,178 and $36,000 of revenue in their latest fiscal years. Lyell Immunopharma grew faster (-41.0% against -92.1%). Addex Therapeutics kept more of each dollar of sales as profit: a net margin of -22448.4% against -762355.6%. Addex Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Addex TherapeuticsADXN, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $36,178 | $36,000 |
| Revenue growth | -92.1% | -41.0% |
| Net income | −$8.1m | −$274m |
| Operating margin | -9390.8% | -748344.4% |
| Net margin | -22448.4% | -762355.6% |
| Return on equity | -97.4% | -87.0% |
| Free cash flow | −$2.6m | −$151m |
| Cash | $2.1m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 161 |
| Market value | $3.7m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |